- Home
- DXR vs CUE Comparison
DXR vs CUE Comparison
Compare DXR & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DXR
- CUE
- Stock Information
- Founded
- DXR 1970
- CUE 2014
- Country
- DXR United States
- CUE United States
- Employees
- DXR N/A
- CUE N/A
- Industry
- DXR Medical/Dental Instruments
- CUE Biotechnology: Pharmaceutical Preparations
- Sector
- DXR Health Care
- CUE Health Care
- Exchange
- DXR Nasdaq
- CUE Nasdaq
- Market Cap
- DXR 46.9M
- CUE 56.1M
- IPO Year
- DXR N/A
- CUE 2018
- Fundamental
- Price
- DXR $13.50
- CUE $0.75
- Analyst Decision
- DXR Strong Buy
- CUE Strong Buy
- Analyst Count
- DXR 1
- CUE 2
- Target Price
- DXR $25.00
- CUE $3.00
- AVG Volume (30 Days)
- DXR 5.1K
- CUE 187.3K
- Earning Date
- DXR 01-01-0001
- CUE 11-13-2025
- Dividend Yield
- DXR N/A
- CUE N/A
- EPS Growth
- DXR 3.46
- CUE N/A
- EPS
- DXR 0.36
- CUE N/A
- Revenue
- DXR $66,306.00
- CUE $8,286,000.00
- Revenue This Year
- DXR N/A
- CUE N/A
- Revenue Next Year
- DXR N/A
- CUE $13.27
- P/E Ratio
- DXR $38.30
- CUE N/A
- Revenue Growth
- DXR N/A
- CUE N/A
- 52 Week Low
- DXR $6.55
- CUE $0.54
- 52 Week High
- DXR $14.00
- CUE $1.99
- Technical
- Relative Strength Index (RSI)
- DXR 66.65
- CUE 54.66
- Support Level
- DXR $13.39
- CUE $0.69
- Resistance Level
- DXR $14.00
- CUE $0.73
- Average True Range (ATR)
- DXR 0.50
- CUE 0.04
- MACD
- DXR 0.13
- CUE 0.01
- Stochastic Oscillator
- DXR 80.93
- CUE 85.70
About DXR Daxor Corporation
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms in a broad range of medical conditions.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.